Pasireotide vs Octreotide
A broader-spectrum somatostatin analog hitting more receptor subtypes. A long-acting somatostatin analog used to suppress GH and other hormones. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Pasireotide | Octreotide | |
|---|---|---|
| Also known as | Signifor | Sandostatin |
| Type | Analog | Analog |
| Evidence | Established | Established |
| Family | Growth & repair | Growth & repair |
| Class | Somatostatin analog (cyclic hexapeptide) | Somatostatin analog (cyclic octapeptide) |
| Receptor | Somatostatin receptors (SSTR1, 2, 3, and 5) | Somatostatin receptors (SSTR2 and SSTR5 preferential) |
| Molecular weight | ~1,047.2 Da | ~1,019.2 Da |
| Half-life | ||
| Based on | Somatostatin | Somatostatin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Pasireotide and Octreotide?
- Pasireotide is an engineered analog based on Somatostatin; Octreotide is an engineered analog based on Somatostatin. Pasireotide signals at Somatostatin receptors (SSTR1, 2, 3, and 5); Octreotide signals at Somatostatin receptors (SSTR2 and SSTR5 preferential).
- How do the half-lives of Pasireotide and Octreotide compare?
- The reported circulating half-life of Pasireotide is ~12 h; Octreotide is ~1.5 h (subcutaneous; LAR depot ~monthly). These are reference values for the native or representative form — educational only, not dosing advice.
- Is Pasireotide the same as Signifor?
- Signifor is a brand name of Pasireotide. This comparison describes the molecules, not branded products.
Prefer the other order? Octreotide vs Pasireotide. Or open the interactive comparison tool to add more molecules.